 |
 |
 |
| 24小時(shí)熱門(mén)版塊排行榜 |
- >論壇更新日志 (939)
- >考研 (93)
- >導(dǎo)師招生 (92)
- >蟲(chóng)友互識(shí) (37)
- >考博 (22)
- >論文道賀祈福 (20)
- >教師之家 (19)
- >碩博家園 (16)
- >無(wú)機(jī)/物化 (15)
- >論文投稿 (14)
- >文獻(xiàn)求助 (11)
- >休閑灌水 (8)
- >公派出國(guó) (7)
- >基金申請(qǐng) (6)
- >找工作 (5)
- >留學(xué)生活 (4)
 |
 |
 |
||
 |
 |
 |
 |
 |
| 6 | 1/1 | 返回列表 |
| 查看: 2007 | 回復(fù): 5 | |||
| 本帖產(chǎn)生 1 個(gè) 翻譯EPI ，點(diǎn)擊這里進(jìn)行查看 | |||
tianya716
|
[交流]
（要明天中午之前）文章摘要翻譯
|
||
|
中文翻譯成英文--翻譯文章的摘要 自己翻譯了一點(diǎn)，但覺(jué)得自己水平太差，需要幫助！ 很急！！因?yàn)槲恼戮鸵蛯徚�，自己已�?jīng)在上班，時(shí)間太少。 摘要 目的 本課題研制瑞格列奈分散片，目的是提高藥物的生物利用度、提高順應(yīng)性和建立科學(xué)嚴(yán)謹(jǐn)?shù)馁|(zhì)量控制標(biāo)準(zhǔn)。研制的瑞格列奈分散片已經(jīng)轉(zhuǎn)讓與**制藥公司進(jìn)行臨床試驗(yàn)和上市銷(xiāo)售。本文研制的瑞格列奈自微乳膠囊，目的是進(jìn)一步提高藥物的生物利用度和減少藥物可能存在的副作用。 方法（1）瑞格列奈分散片處方和工藝研究 采用單因素試驗(yàn)，以分散均勻性和溶出度為指標(biāo)，對(duì)輔料種類(lèi)的進(jìn)行篩選；采用正交試驗(yàn)，以分散均勻性、溶出度為指標(biāo)，對(duì)輔料用量進(jìn)行優(yōu)化，并最終確定處方。采用單因素試驗(yàn)對(duì)等量遞增混勻法-濕法制粒工藝、溶劑分散混勻法-濕法制粒工藝和等量遞增混勻法-粉末直接壓片工藝，進(jìn)行比較，優(yōu)選出最佳的工藝。 （2）瑞格列奈分散片含量測(cè)定方法的研究 以回收率和pH耐用性為評(píng)價(jià)指標(biāo)，對(duì)三種瑞格列奈片劑的含量測(cè)定方法進(jìn)行比較，最終確定美國(guó)藥典的瑞格列奈片劑的含量測(cè)定方法較好。并依據(jù)美國(guó)藥典的瑞格列奈片劑的含量測(cè)定方法，建立了瑞格列奈分散片的含量測(cè)定方法。 （3）瑞格列奈分散片溶出度測(cè)定方法的研究 通過(guò)對(duì)瑞格列奈分散片溶出介質(zhì)和轉(zhuǎn)速的篩選，建立了科學(xué)合理的溶出度測(cè)定方法，并對(duì)瑞格列奈分散片進(jìn)行了體外評(píng)價(jià)研究。 （4）瑞格列奈分散片有關(guān)物質(zhì)的研究 通過(guò)酸、堿、熱破環(huán)試驗(yàn)，對(duì)瑞格列奈可能存在有關(guān)物質(zhì)進(jìn)行分離，并通過(guò)二極管陣列檢測(cè)器對(duì)藥物主峰的純度進(jìn)行檢查，建立科學(xué)嚴(yán)謹(jǐn)?shù)娜鸶窳心魏腿鸶窳心畏稚⑵挠嘘P(guān)物質(zhì)的測(cè)定方法。 （5）瑞格列奈分散片的加速穩(wěn)定性考察 對(duì)瑞格列奈分散片進(jìn)行了6個(gè)月的加速穩(wěn)定性試驗(yàn)，并據(jù)此預(yù)測(cè)出藥物的有效期為2年。 （6）瑞格列奈自微乳膠囊的研制 采用正交試驗(yàn)和三元相圖，以溶解度、透光率、粒徑指標(biāo)，篩選瑞格列奈自微乳膠囊的處方，并進(jìn)行質(zhì)量評(píng)價(jià)研究和初步穩(wěn)定性考察。 結(jié)果 （1）瑞格列奈分散片 成功優(yōu)選出瑞格列奈分散片的處方，并建立了科學(xué)嚴(yán)謹(jǐn)?shù)馁|(zhì)量標(biāo)準(zhǔn)。自制瑞格列奈分散片比市售的普通片劑的溶出速率和30min的溶出度均明顯增加，初步達(dá)到提高藥物生物利用度的目的。 （2）瑞格列奈自微乳膠囊 成功優(yōu)選出瑞格列奈自微乳膠囊的處方，并建立了質(zhì)量控制和評(píng)價(jià)標(biāo)準(zhǔn)。瑞格列奈自微乳膠囊，與市售的普通片劑和自制的普通膠囊相比，溶出速率和30min的溶出度均明顯增加，初步達(dá)到提高藥物生物利用度的目的。 結(jié)論 篩選的瑞格列奈分散片和自微乳膠囊的處方合理，制備工藝簡(jiǎn)單可行，質(zhì)量標(biāo)準(zhǔn)能有效控制質(zhì)量。制備的瑞格列奈分散片和自微乳膠囊符合制劑質(zhì)量要求。通過(guò)體外評(píng)價(jià)研究，所研制的瑞格列奈分散片和自微乳膠囊，與市售的普通片劑和普通膠囊相比，溶出明顯加快，初步達(dá)到提高藥物生物利用度的目的。 關(guān)鍵詞：瑞格列奈；分散片；自微乳膠囊；正交試驗(yàn)；質(zhì)量標(biāo)準(zhǔn)；三元相圖；星點(diǎn)-效應(yīng)面設(shè)計(jì) Abstract Objective The purpose of this subject is developping repaglinide dispersible tablets, aims to improve the bioavailability of drugs, improve compliance and the establishment of scientific and strict quality control standards. Repaglinide dispersible tablets have been sold to the U.S. **Zhongshan pharmaceutical company. This article developed the microemulsion capsule of repaglinide, aims to further improve the bioavailability of the drug and reduce drug side effects that may exist. Methods (1) repaglinide dispersible tablets prescription and technology [ Last edited by tianya716 on 2010-5-18 at 18:36 ] |
回復(fù)此樓» 猜你喜歡
293求調(diào)劑
已經(jīng)有14人回復(fù)
-
0703化學(xué)336分求調(diào)劑
已經(jīng)有6人回復(fù)
-
304求調(diào)劑
已經(jīng)有9人回復(fù)
-
281求調(diào)劑（0805）
已經(jīng)有8人回復(fù)
-
環(huán)境領(lǐng)域全國(guó)重點(diǎn)實(shí)驗(yàn)室招收博士1-2名
已經(jīng)有3人回復(fù)
-
材料專(zhuān)碩306英一數(shù)二
已經(jīng)有10人回復(fù)
-
301求調(diào)劑
已經(jīng)有6人回復(fù)
-
一志愿天津大學(xué)化學(xué)工藝專(zhuān)業(yè)（081702）315分求調(diào)劑
已經(jīng)有7人回復(fù)
-
302求調(diào)劑
已經(jīng)有6人回復(fù)
-
26博士申請(qǐng)
已經(jīng)有3人回復(fù)
mmyytiger
至尊木蟲(chóng) (職業(yè)作家)
院士
- 翻譯EPI: 7
- 應(yīng)助: 15 (小學(xué)生)
- 金幣: 12669.3
- 紅花: 10
- 帖子: 3246
- 在線: 272.5小時(shí)
- 蟲(chóng)號(hào): 851420
- 注冊(cè): 2009-09-19
- 性別: GG
- 專(zhuān)業(yè): 計(jì)算機(jī)網(wǎng)絡(luò)
tianya716(金幣+3, 翻譯EPI+1):貌是工具翻譯的 2010-05-18 22:23:13
sirljz:禁止工具直接翻譯的回帖 2010-05-20 17:32:32
sirljz:禁止工具直接翻譯的回帖 2010-05-20 17:32:32
|
Abstract objective The purpose of this subject develop repaglinide, dispersible tablets, aims to improve the bioavailability of drugs, improve compliance and the establishment of scientific and strict quality control standards. Repaglinide dispersible tablets have been developed and ** transfer clinical trials and pharmaceutical companies on sale. This article developed from the microemulsion capsule repaglinide, aims to further improve the bioavailability of drugs and reduce drug side effects that may exist. Methods (1) repaglinide tablet formulation and technology of single factor experiments to spread the uniformity and dissolution rate as an index of the types of screening accessories; orthogonal test, to spread uniformity, dissolution rate for the index for accessories to optimize the dosage and ultimately determine the prescription. Single-factor test and the equivalent incremental mixing method - wet granulation process, solvent dispersion mixing method - wet granulation process and the equal incremental mixing method - the powder pellets technology, comparing the optimized process . (2) Determination of repaglinide tablet study to recovery and durability for the evaluation of pH indicator, the three methods the determination of repaglinide tablets compared to finalize the United States Pharmacopoeia repaglinide Determination tablets better. And according to the United States Pharmacopoeia method for the determination of repaglinide tablets, dispersible tablets was established method for the determination of repaglinide. (3) determination of repaglinide in tablet dissolution studies on repaglinide tablet dissolution medium and the speed of screening, the establishment of a scientific and reasonable method of dissolution test, and repaglinide were dispersible tablets In vitro evaluation. (4) repaglinide tablet related substances by acid, alkali, heat broken ring test, the material on repaglinide may be isolated by diode array detector and the main peak of the purity of the drug inspection, the establishment of rigorous science and repaglinide repaglinide tablet Determination of related substances. (5) the acceleration of dispersible tablets stability of repaglinide on repaglinide tablet was 6 months of accelerated stability test, and to predict the drug is valid for 2 years. (6) repaglinide from microemulsion capsule by orthogonal experiment and the ternary phase diagram, with solubility, light transmittance, particle size index, selection repaglinide from microemulsion capsule formulation, and evaluated the quality of Stability study and preliminary. Results (1) successfully optimized repaglinide repaglinide tablet dispersible tablets prescription, and the establishment of a scientific rigorous quality standards. Home Repaglinide dispersible tablets compared with ordinary commercial dissolution rate and dissolution of 30min were significantly increased, initially to improve drug bioavailability purposes. (2) of repaglinide from microemulsion capsule successfully optimized microemulsion capsules from prescription repaglinide, and the establishment of quality control and evaluation criteria. Repaglinide from microemulsion capsule, and general commercial and home-made capsules, tablets compared, the release rate and the dissolution of 30min were significantly increased, initially to improve drug bioavailability purposes. Conclusion screening repaglinide tablet and capsule from the microemulsion reasonable prescription, preparation is simple and feasible, effective quality control quality standards. Preparation of repaglinide tablet and capsule from the microemulsion formulation meet quality requirements. In vitro evaluation studies, the development of repaglinide in tablet and capsule from the microemulsion, with commercially available conventional tablets and capsules, compared to significantly speed up the dissolution, initially to improve drug bioavailability purposes. Keywords: Repaglinide; tablet; from microemulsion capsule; orthogonal test; quality standards; ternary phase diagram; Star points - response surface design |
2樓2010-05-18 18:44:13
tianya716 
木蟲(chóng) (正式寫(xiě)手)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 7102.4
- 散金: 34
- 帖子: 618
- 在線: 257.1小時(shí)
- 蟲(chóng)號(hào): 463563
- 注冊(cè): 2007-11-20
- 專(zhuān)業(yè): 藥劑學(xué)
3樓2010-05-18 19:40:32
benmao_mogu
鐵桿木蟲(chóng) (著名寫(xiě)手)
- 翻譯EPI: 51
- 應(yīng)助: 16 (小學(xué)生)
- 金幣: 5474.7
- 散金: 2632
- 紅花: 24
- 帖子: 1539
- 在線: 197.5小時(shí)
- 蟲(chóng)號(hào): 992763
- 注冊(cè): 2010-04-09
- 性別: GG
- 專(zhuān)業(yè): 化學(xué)反應(yīng)工程
4樓2010-05-18 19:44:50
tianya716
木蟲(chóng) (正式寫(xiě)手)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 7102.4
- 散金: 34
- 帖子: 618
- 在線: 257.1小時(shí)
- 蟲(chóng)號(hào): 463563
- 注冊(cè): 2007-11-20
- 專(zhuān)業(yè): 藥劑學(xué)
5樓2010-05-18 21:15:50
butterfly7727
金蟲(chóng) (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 1000.6
- 帖子: 14
- 在線: 107.4小時(shí)
- 蟲(chóng)號(hào): 588580
- 注冊(cè): 2008-08-29
- 專(zhuān)業(yè): 藥劑學(xué)
★ ★
sirljz(金幣+2):拒絕工具直接翻譯的回帖 2010-05-20 17:33:08
木子小木蟲(chóng)(金幣+3):謝謝交流！ 2010-05-20 17:33:25
木子小木蟲(chóng)(金幣-3):評(píng)閱重復(fù)了，不好意思！ 2010-05-20 20:42:44
sirljz(金幣+2):拒絕工具直接翻譯的回帖 2010-05-20 17:33:08
木子小木蟲(chóng)(金幣+3):謝謝交流！ 2010-05-20 17:33:25
木子小木蟲(chóng)(金幣-3):評(píng)閱重復(fù)了，不好意思！ 2010-05-20 20:42:44
|
Abstract Objective The purpose of this subject is developping repaglinide dispersible tablets, aims to improve the bioavailability of drugs, improve compliance and the establishment of scientific and strict quality control standards. Repaglinide dispersible tablets have been sold to the U.S. Anshi Zhongshan pharmaceutical company. This article developed the Self-emusifying microemulsion Capsules of repaglinide, aims to further improve the bioavailability of the drug and reduce drug side effects that may exist. Methods (1) repaglinide dispersible tablets prescription and technology Single-factor test to sift the types of supplementary material as an index of spread uniformity and dissolution rate; Orthogonal test to optimize the amount of the supplementary material as an index to spread uniformity and dissolution rate; Ultimately determine the prescription.compared the equivalent incremental mixing method-wet granulation process, solvent dispersion mixing method-wet granulation process and the equal incremental mixing method -the powder pellets technology by Single-factor test to obtain optimized process. (2) Determination of Repaglinide dispersible tablets With the index of recovery and pH durability, compared three methods of determination of repaglinide tablets. Ultimately obtained the United States Pharmacopoeia method for the determination of repaglinide tablets is better. And according to the United States Pharmacopoeia method for the determination of repaglinide tablets, Established method for the determination of repaglinide dispersible tablets. (3)Dissolution method for Repaglinide dispersible tablets By sifting repaglinide dispersible tablets dissolution medium and rotation speed, Established a scientific and reasonable method of dissolution, and in vitro evaluation of repaglinide dispersible tablets conducted. (4)The related substances of Repaglinide dispersible tablets By acid, alkali and heat damage tests, the may exist related substances of Repaglinide was separated, the purity of main drugs peak checked by Diode array detector. Establishment rigorous and scientific method of determination of related substances for repaglinide and repaglinide dispersible tablets. (5) Accelerated stability of repaglinide dispersible tablets 6 months of accelerated stability test was used for the repaglinide dispersible tablets, And to predict the drug is valid for 2 years. (6) Preparation repaglinide self- emusifying microemulsion Capsules Orthogonal test and ternary phase diagram, with index of solubility, light transmittance, particle size index, selection prescription of repaglinide self-emusifying microemulsion capsules. And to evaluate the quality of repaglinide self-emusifying microemulsion capsules and preliminary stability study. Results (1)Repaglinide dispersible tablets The reasonable prescription was obtained and easy manipulation and reliable quality control was achieved. And the prepared dispersible tablets met the pharmaceutical requirements. Repaglinide dispersible tablets compared with commercial products, dissolution rate and dissolution of 30min were significantly increased, initially to improve drug bioavailability purposes. (2) Repaglinide self-emusifying microemulsion Capsules The reasonable formulation was obtained and easy manipulation and reliable quality control was achieved for repaglinide self-emusifying microemulsion capsules. Compared with commercial products and general capsules, tablets, the release rate and the dissolution of 30min of repaglinide self-emusifying microemulsion capsules were significantly increased, initially to improve drug bioavailability purposes. Keywords：Repaglinide; self-emulsifying drug delivery systems; orthogonal test; ternary phase diagram; Star points-response surface design |
6樓2010-05-20 17:22:54
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 tianya716 的主題更新
| 6 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 311求調(diào)劑 +9 | 冬十三 2026-03-15 | 10/500 |
|
|---|---|---|---|---|
|
[基金申請(qǐng)] 被我言中：新模板不強(qiáng)調(diào)格式了，假專(zhuān)家開(kāi)始管格式了 +4 | beefly 2026-03-14 | 4/200 |
|
|
|
[考研] 277調(diào)劑 +5 | 自由煎餅果子 2026-03-16 | 6/300 |
|
|
|
[考研] 341求調(diào)劑 +5 | 搗蛋豬豬 2026-03-11 | 7/350 |
|
|
|
[考研] 328求調(diào)劑，英語(yǔ)六級(jí)551，有科研經(jīng)歷 +3 | 生物工程調(diào)劑 2026-03-16 | 8/400 |
|
|
|
[考研] 材料工程專(zhuān)碩調(diào)劑 +5 | 204818@lcx 2026-03-17 | 5/250 |
|
|
|
[考研] 材料專(zhuān)碩274一志愿陜西師范大學(xué)求調(diào)劑 +5 | 薛云鵬 2026-03-13 | 5/250 |
|
|
|
[考研] 藥學(xué)383 求調(diào)劑 +3 | 藥學(xué)chy 2026-03-15 | 4/200 |
|
|
|
[考研] 304求調(diào)劑 +5 | 素年祭語(yǔ) 2026-03-15 | 5/250 |
|
|
|
[教師之家] 焦慮 +7 | 水冰月月野兔 2026-03-13 | 9/450 |
|
|
|
[考研] 0856求調(diào)劑 +3 | 劉夢(mèng)微 2026-03-15 | 3/150 |
|
|
|
[考博] 東華理工大學(xué)化材專(zhuān)業(yè)26屆碩士博士申請(qǐng) +6 | zlingli 2026-03-13 | 6/300 |
|
|
|
[考研] 復(fù)試調(diào)劑 +4 | z1z2z3879 2026-03-14 | 5/250 |
|
|
|
[考研] 266求調(diào)劑 +4 | 學(xué)員97LZgn 2026-03-13 | 4/200 |
|
|
|
[考研] 337一志愿華南理工0805材料求調(diào)劑 +7 | mysdl 2026-03-11 | 9/450 |
|
|
|
[考研] 26調(diào)劑/材料科學(xué)與工程/總分295/求收留 +9 | 2026調(diào)劑俠 2026-03-12 | 9/450 |
|
|
|
[考研] 材料工程調(diào)劑 +4 | 咪咪空空 2026-03-11 | 4/200 |
|
|
|
[考研] 310求調(diào)劑 +3 | 【上上簽】 2026-03-11 | 3/150 |
|
|
|
[考研] 一志愿211化學(xué)學(xué)碩310分求調(diào)劑 +8 | 努力奮斗112 2026-03-12 | 9/450 |
|
|
|
[考研] 308求調(diào)劑 +3 | 是Lupa啊 2026-03-12 | 3/150 |
|